News

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...
STAT3d

FDA approves Ionis drug that prevents swelling attacks caused by a rare disease

Ionis Pharmaceuticals won FDA approval for a drug that prevents painful swelling attacks triggered by a rare genetic ...
BioSpace2d

Ionis Wins Approval For First RNA-Targeted Prophylactic for Rare Swelling Disease

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...
The Pharma Letter2d

FDA approves Ionis’ Dawnzera as first RNA-targeted therapy for HAE

The US Food and Drug Administration (FDA) has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of ...
PharmExec2d

FDA Approves Ionis Pharmaceuticals’ Dawnzera for Hereditary Angioedema

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

US FDA approves Ionis' drug for rare genetic disorder

The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe ...
The American Journal of Managed Care3d

FDA Approves First RNA-Targeted Treatment for Hereditary Angioedema

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

Ionis Gets FDA OK of Dawnzera in Hereditary Angioedema

Ionis on Thursday said the FDA green light covers Dawnzera for prophylaxis to prevent attacks of hereditary angioedema in patients 12 years of age and older and makes the drug is the first and only ...
Medpage Today on MSN2d

RNA-Targeted Drug Approved for Preventing Hereditary Angioedema Attacks

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...
Managed Healthcare Executive2d

FDA Approves First in Class Therapy for Hereditary Angioedema

Developed by Ionis Pharmaceuticals, Dawnzera is the first RNA-targeted medicine approved for HAE, designed to target plasma ...
The Pharma Letter9h

The week in pharma: action, reaction and insight – week to August 22

The US Food and Drug Administration (FDA) granted approval for a second treatment for metabolic dysfunction-associated ...